Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGLE Aeglea BioTherapeutics		$11.47	$2.66 ▼ $32.75	$48.64M	2.57	95,409 shs	43,300 shs
ALBO Albireo Pharma	$44.15	$44.17	$16.02 ▼ $45.23	$913.91M	1.03	704,539 shs	1.24 million shs
CTMX CytomX Therapeutics	$2.39 -1.2%	$2.26	$0.40 ▼ $3.10	$192.68M	2.05	2.21 million shs	815,909 shs
MRUS Merus	$55.62 +2.1%	$50.76	$33.19 ▼ $62.98	$3.85B	1	732,623 shs	694,277 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGLE Aeglea BioTherapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ALBO Albireo Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
CTMX CytomX Therapeutics	-1.24%	+0.84%	-13.09%	+278.46%	+68.31%
MRUS Merus	+2.06%	+5.78%	+1.85%	+28.69%	-2.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGLE Aeglea BioTherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	4.1891 of 5 stars	3.5	1.0	0.0	4.7	2.4	1.7	1.3
MRUS Merus	1.9209 of 5 stars	3.6	1.0	0.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGLE Aeglea BioTherapeutics	0.00	N/A	N/A	N/A
ALBO Albireo Pharma	0.00	N/A	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.33	123.15% Upside
MRUS Merus	3.14	Buy	$84.64	52.17% Upside

Current Analyst Ratings Breakdown

Latest ALBO, MRUS, CTMX, and AGLE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGLE Aeglea BioTherapeutics	$2.33M	0.00	N/A	N/A	($60.61) per share	0.00
ALBO Albireo Pharma	$40.58M	22.52	N/A	N/A	$9.11 per share	4.85
CTMX CytomX Therapeutics	$138.10M	1.40	$0.36 per share	6.69	($0.01) per share	-239.00
MRUS Merus	$36.13M	106.54	N/A	N/A	$9.46 per share	5.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGLE Aeglea BioTherapeutics	-$83.82M	-$75.59	N/A	N/A	N/A	-22,195.36%	-132.05%	-146.87%	N/A
ALBO Albireo Pharma	-$34.03M	-$6.72	N/A	N/A	N/A	-228.51%	-97.13%	-46.89%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.48	4.98	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)

Latest ALBO, MRUS, CTMX, and AGLE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGLE Aeglea BioTherapeutics	N/A	N/A	N/A	N/A	N/A
ALBO Albireo Pharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGLE Aeglea BioTherapeutics	N/A	4.59	4.59
ALBO Albireo Pharma	N/A	6.32	6.23
CTMX CytomX Therapeutics	N/A	1.73	1.73
MRUS Merus	N/A	5.86	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGLE Aeglea BioTherapeutics	N/A
ALBO Albireo Pharma	94.25%
CTMX CytomX Therapeutics	67.77%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
AGLE Aeglea BioTherapeutics	6.60%
ALBO Albireo Pharma	6.90%
CTMX CytomX Therapeutics	6.60%
MRUS Merus	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGLE Aeglea BioTherapeutics	69	4.05 million	3.78 million	Optionable
ALBO Albireo Pharma	130	20.70 million	19.27 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable

ALBO, MRUS, CTMX, and AGLE Headlines

Recent News About These Companies

Cincinnati Children’s, Christ Hospital partner with developer Merus for project in Cold Spring

July 12 at 12:24 PM | nkytribune.comN

Peter B. Silverman Sells 6,695 Shares of Merus N.V. (NASDAQ:MRUS) Stock

July 12 at 6:15 AM | insidertrades.com

Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating

July 12 at 2:55 AM | marketbeat.com

Merus N.V. (NASDAQ:MRUS) COO Sells $368,225.00 in Stock

July 11, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock

July 11, 2025 | marketbeat.com

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

July 11, 2025 | zacks.com

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

July 9, 2025 | msn.com

KBC Group NV Sells 54,333 Shares of Merus N.V. (NASDAQ:MRUS)

July 8, 2025 | marketbeat.com

Moody Aldrich Partners LLC Has $4.56 Million Holdings in Merus N.V. (NASDAQ:MRUS)

July 4, 2025 | marketbeat.com

Stocks To Watch: Merus Sees RS Rating Rise To 84

July 2, 2025 | msn.com

Merus N.V.: Making Progress

June 29, 2025 | seekingalpha.com

Merus N.V. (MRUS) Latest Stock News & Headlines - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Stocks Showing Rising Market Leadership: Merus Earns 81 RS Rating

June 25, 2025 | msn.com

Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock

June 25, 2025 | insidertrades.com

Peter B. Silverman Sells 34,000 Shares of Merus N.V. (NASDAQ:MRUS) Stock

June 24, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

June 11, 2025 | seekingalpha.com

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

June 10, 2025 | tipranks.com

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

June 9, 2025 | tipranks.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | msn.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBO, MRUS, CTMX, and AGLE Company Descriptions

Aeglea BioTherapeutics NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Albireo Pharma NASDAQ:ALBO

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

CytomX Therapeutics NASDAQ:CTMX

$2.39 -0.03 (-1.24%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.39 0.00 (0.00%)

As of 07/14/2025 07:35 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Merus NASDAQ:MRUS

$55.62 +1.12 (+2.06%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$55.66 +0.04 (+0.07%)

As of 07/14/2025 04:11 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time